ArticleAnnals of hematology2025
Internal tandem duplications of FLT3 containing exogenous sequences are associated with poor clinical outcomes in acute myeloid leukemia.
Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single cell Raman spectroscopic profiles predict treatment responses in patients withFrontiers in cell and developmental biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The heterogeneity in internal tandem duplications (ITDs) of FMS-like tyrosine kinase 3 (FLT3) results in diverse clinical outcomes for acute myeloid leukemia (AML) patients with FLT3-ITD mutations. This study retrospectively analyzed 124 FLT3-ITD-positive AML patients, aiming to evaluate How ITDs with exogenous sequences affect the response to induction therapy and long-term prognosis. Among them, 45.97% (57/124) had ITDs with exogenous sequences, classified as the insertion group. The remaining 54.03% (67/124) had only repetitions of the original FLT3 sequence, classified as the duplication group. Comparisons between these two groups revealed that the rates of composite complete remission (CRc) (59.09% vs. 81.03%, P = 0.017) and negative measurable residual disease (MRD) identified by multiparameter flow cytometry (MFC) (25.00% vs. 48.28%, P = 0.018) were significantly lower in the insertion group than those in the duplication group after the first cycle of induction therapy. Moreover, survival analysis conducted on 68 patients who received at least two cycles of consolidation therapy revealed that patients in the insertion group had significantly lower relapse-free survival (RFS) (2-year RFS: 50.70% ± 10.40% vs. 71.40% ± 8.90%, P = 0.033) and overall survival (OS) (2-year OS: 52.90% ± 10.20% vs. 79.00% ± 7.90%, P = 0.017) compared with those in the duplication group. Cox regression analysis identified ITD types, DNMT3A co-mutations, MFC-MRD after the second cycle (C2) of chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) in the first CR (CR1) as independent factors affecting RFS and OS. Furthermore, nomograms were employed to predict RFS and OS, and a new prognostic re-stratification model based on ITD types for FLT3-ITD-positive AML was proposed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.